United States Patent 8,809,305: Scope, Claims, Expiration, and Adapalene-Benzoyl Peroxide Patent Landscape

U.S. Patent No. 8,809,305 protects a long-term acne-treatment regimen using a fixed-dose topical combination of adapalene and benzoyl peroxide. The independent claim is method-of-treatment coverage, not composition-of-matter coverage. It requires treatment at least once every two days for at least six months, with a formulation containing 0.1% to 0.3% adapalene and exactly 2.5% benzoyl peroxide as the only anti-acne active ingredients. The patent is associated with Galderma’s Epiduo product family and has an ordinary patent-term endpoint in 2027, subject to any applicable patent-term adjustment or extension.

What does U.S. Patent 8,809,305 protect?

The patent protects a dosing regimen for acne vulgaris using a fixed-dose combination of:

Required element	Claim 1 requirement
Disease	Acne vulgaris
Administration route	Topical
Treatment frequency	At least once every two days
Treatment duration	At least six months
Adapalene concentration	0.1% to 0.3% by weight
Benzoyl peroxide concentration	2.5% by weight
Active ingredients	Adapalene and benzoyl peroxide only
Formulation	Pharmaceutically acceptable medium
Use	Long-term treatment of affected skin

The patent does not broadly claim every adapalene-benzoyl peroxide product. Its principal coverage is tied to how the product is used over time.

A product containing adapalene and benzoyl peroxide could fall outside claim 1 if it is used for less than six months, applied less frequently than once every two days, contains benzoyl peroxide at a concentration other than 2.5%, or contains a third anti-acne active ingredient. Those distinctions do not automatically eliminate infringement risk under other patent claims or other patents in the product family.

How should claim 1 of U.S. Patent 8,809,305 be interpreted?

Claim 1 is a combination of product and regimen limitations. A claimant would need to establish the required formulation characteristics and the treatment conduct.

The principal limitations are:

The patient must have acne vulgaris.
The medication must be applied topically to an affected skin area.
Treatment must occur at least once every two days.
Treatment must continue for at least six months.
The formulation must contain adapalene at 0.1% to 0.3% by weight.
The formulation must contain benzoyl peroxide at exactly 2.5% by weight.
Adapalene and benzoyl peroxide must be the only anti-acne active ingredients.
The actives must be in a fixed-dose combination.

The phrase "at least once every two days" covers daily administration and administration on alternating days. It does not necessarily cover administration every three days or less frequently. Claims 4 and 5 expressly narrow the regimen to once daily and once every two days, respectively.

The requirement that the two actives be the "only anti-acne active ingredients" is important. Excipients, preservatives, penetration enhancers, humectants and other inactive ingredients would not ordinarily defeat this limitation. A formulation containing salicylic acid, clindamycin, erythromycin, dapsone or another anti-acne active could fall outside claim 1, subject to claim construction and the scope of other claims.

What are the dependent claims in U.S. Patent 8,809,305?

The dependent claims narrow treatment duration, dosing frequency, administration timing, formulation type, concentration and patient population.

Claim	Added limitation
2	Treatment for at least 12 months
3	Treatment for at least 9 months
4	Administration once daily
5	Administration every two days
6	Administration in the evening after washing the affected skin
7	Gel composition
8	Once-daily administration for at least 9 months
9	Once-daily administration for at least 12 months
10	0.1% adapalene and 2.5% benzoyl peroxide
11	20-100 non-inflammatory lesions, 20-50 inflammatory lesions, and no active nodules or cysts

Claims 8 and 9 are commercially significant because they combine the most common dosing instruction, once-daily use, with extended treatment periods. Claim 10 is narrower than claim 1 and corresponds to the conventional Epiduo concentration. Claim 11 defines a moderate acne population and excludes patients with active nodules or cysts.

What formulation is covered by U.S. Patent 8,809,305?

The broadest claim covers a pharmaceutically acceptable topical medium. It does not require a gel. Claim 7 separately narrows the scope to a gel composition.

The most commercially relevant formulation is a gel containing:

0.1% adapalene;
2.5% benzoyl peroxide; and
no other anti-acne active ingredient.

This concentration corresponds to Epiduo topical gel, marketed by Galderma in the United States under NDA 022320. The patent does not require a particular trade name, container, preservative system, carbomer, surfactant or manufacturing process unless those limitations appear in a separate claim or related patent.

The claim structure leaves room for non-gel formulations, including creams, lotions or other topical vehicles, under claim 1 if they satisfy the remaining limitations. Claim 7 is narrower because it requires a gel.

When does U.S. Patent 8,809,305 lose exclusivity?

U.S. Patent No. 8,809,305 issued on August 19, 2014. Its ordinary patent term is calculated from the applicable nonprovisional filing or priority framework and is expected to run into 2027. Public patent-family records associate the patent with a September 28, 2007 priority date, producing an ordinary expected expiration date of September 28, 2027, before accounting for any patent-term adjustment.

Event	Date
Earliest reported priority date	September 28, 2007
U.S. patent grant	August 19, 2014
Ordinary expected term endpoint	September 28, 2027
Relevant exclusivity type	Patent protection for method of treatment
Patent-term adjustment	Must be confirmed from the USPTO patent face and maintenance records

The patent should not be treated as enforceable after the term endpoint without checking the official USPTO term calculation. Patent-term adjustment can move the expiration date later. Patent-term extension under 35 U.S.C. § 156 is generally associated with regulatory review of certain products, but the existence and scope of any extension must be verified independently from the patent record and Orange Book.

The patent’s expiration does not necessarily remove every barrier to generic or follow-on competition. Other patents may cover the formulation, manufacturing process, delivery vehicle, concentration, labeling or separate methods of use.

What is the Orange Book status of U.S. Patent 8,809,305?

The Orange Book question must be analyzed at the NDA level rather than from the patent number alone. FDA Orange Book listings identify patents submitted by the NDA holder and assign use codes where applicable. A method-of-treatment patent may be listed for an approved product even though it does not claim the active ingredient itself. [FDA, 2024a]

For Epiduo, the commercially relevant regulatory product is the adapalene 0.1% and benzoyl peroxide 2.5% topical gel approved under NDA 022320. The significance of Patent 8,809,305 depends on whether it appears in the current Orange Book for that NDA, the use code assigned to it, and whether the patent was delisted, expired, or retained.

The patent’s claim language would support an Orange Book use code directed to long-term treatment of acne vulgaris with the fixed-dose combination. A generic applicant could address such a listing through:

a Paragraph IV certification alleging invalidity, unenforceability or noninfringement;
a section viii statement seeking approval for a label that omits the patented use, if FDA permits the carve-out; or
a Paragraph III certification deferring approval until patent expiration.

The practical effect depends on the scope of the proposed generic label. A generic label that instructs once-daily use for acne treatment could create greater exposure than a label that omits the long-term treatment language, although FDA labeling and patent infringement analysis are separate issues.

How do Paragraph IV challenges affect this patent?

A Paragraph IV certification would put the patent holder on notice that the applicant contends that the patent is invalid, unenforceable or will not be infringed. Under the Hatch-Waxman framework, timely patent litigation can trigger a 30-month stay of ANDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions. [U.S. Congress, 1984]

For this patent, likely Paragraph IV theories would include:

Noninfringement

A generic applicant could argue that its proposed label does not require:

treatment for at least six months;
administration at least once every two days;
the claimed concentration range;
benzoyl peroxide at exactly 2.5%;
adapalene and benzoyl peroxide as the only anti-acne actives; or
the lesion profile in claim 11.

The strongest noninfringement position would generally arise from a label that omits the patented long-term regimen. That position can be complicated if the product is marketed for the same clinical use and physicians routinely prescribe it under the patented regimen.

Invalidity

Potential validity challenges include:

anticipation by prior clinical studies or publications describing long-term adapalene and benzoyl peroxide use;
obviousness based on known adapalene, benzoyl peroxide and maintenance-treatment regimens;
lack of written description or enablement for the full 0.1% to 0.3% adapalene range;
indefiniteness involving "safe and effective," "long-term" treatment or "only anti-acne active ingredients"; and
lack of patentable distinction between the claimed regimen and approved or publicly disclosed use.

The patent’s strength depends heavily on the prosecution history, cited prior art, clinical evidence and any claim amendments made during examination. The claims are narrower than a composition patent but may benefit from clinical data showing that long-term use was safe and effective at the claimed concentrations.

What patent litigation affects U.S. Patent 8,809,305?

Patent 8,809,305 is a method-of-use patent. Litigation risk would most likely arise in connection with an ANDA for adapalene and benzoyl peroxide gel 0.1%/2.5%, an authorized generic, or a competing branded product.

A complete litigation assessment requires checking:

FDA Orange Book patent listings;
FDA Paragraph IV notice records;
complaints filed in federal district courts;
Patent Trial and Appeal Board proceedings;
ANDA litigation docket entries;
settlements and consent judgments; and
maintenance-fee and expiration records.

The patent number alone does not establish that litigation is pending, resolved or absent. A litigation search must distinguish cases involving the patent from cases involving related Galderma patents covering Epiduo or other adapalene products. Related patents may generate meaningful market restrictions even if Patent 8,809,305 is not asserted.

What companies compete with or challenge the Epiduo patent estate?

The relevant competitive field includes:

Competitor type	Product or strategy	Principal patent issue
Generic manufacturers	Adapalene/benzoyl peroxide 0.1%/2.5% gel	Paragraph IV, section viii, or post-expiration entry
Authorized generic supplier	Same or substantially equivalent product	Commercial entry without independent clinical differentiation
Alternative topical products	Adapalene alone, benzoyl peroxide alone, tretinoin, clindamycin combinations	Avoidance of the fixed-dose combination claims
New topical therapies	Trifarotene, clascoterone and other acne products	Clinical substitution rather than direct formulation competition
Compounded products	Pharmacy-compounded combinations	Regulatory, quality and infringement exposure varies

A product containing adapalene alone does not satisfy the fixed-dose combination requirement. A benzoyl peroxide product alone also falls outside the claims. Direct competition is strongest from products containing both adapalene and benzoyl peroxide at the claimed concentrations.

How strong is the patent estate for Epiduo?

Patent 8,809,305 provides targeted protection rather than broad molecule or composition protection.

Strengths

It covers the commercially important 0.1%/2.5% combination through claim 10.
It covers daily use, the most commercially conventional regimen.
It reaches long-term treatment, which may be important for maintenance therapy.
It includes both formulation and patient-population limitations.
It can create ANDA litigation risk even though the claims are method-of-use claims.

Weaknesses

The independent claim requires a specific treatment duration and dosing frequency.
The claims do not broadly cover adapalene or benzoyl peroxide individually.
A generic may seek a label that omits or narrows the patented use.
The claimed regimen may face obviousness arguments based on routine acne maintenance therapy.
Claim 11’s lesion-count limitations may be difficult to prove and may narrow practical enforcement.

The estate is strongest against a product whose labeling expressly instructs once-daily application of 0.1% adapalene/2.5% benzoyl peroxide for long-term acne treatment. It is weaker against products with different strengths, different active ingredients, different labels or different treatment instructions.

What generic launch scenarios exist?

Launch after patent expiration

A generic can launch after all relevant patents and regulatory exclusivities expire, subject to FDA approval. This is the lowest litigation-risk scenario.

Launch after a successful Paragraph IV challenge

If a court invalidates or finds noninfringement of the relevant patent, the ANDA applicant may launch, subject to other patents and regulatory requirements.

Launch under a carved-out label

A generic may seek approval with patented method-of-use language omitted if FDA permits the labeling strategy. The manufacturer must then control promotional activity and product information to reduce inducement exposure.

At-risk launch

A manufacturer may launch before final resolution of patent litigation. This exposes it to damages, possible injunctive relief and loss of market access if the patent is upheld and infringement is found.

Settlement-based entry

A settlement could establish an agreed launch date, authorized-generic arrangement, license, supply agreement or other commercial terms. The business impact depends on whether the agreement restricts entry before patent expiration and whether it is reviewed under FTC and DOJ pharmaceutical-settlement policies.

What manufacturing and geographic barriers remain?

The claims do not require a particular manufacturing process. They are directed primarily to the treatment regimen and formulation composition. A manufacturer therefore cannot avoid the patent merely by changing the mixing sequence, packaging, tube, preservative system or production site if the marketed product and labeled use satisfy the claims.

Geographic scope is limited to the United States. A separate analysis is required for corresponding patents in Europe, Canada, Japan, Australia and other jurisdictions. Foreign family members may have different claim scope, expiration dates, prosecution histories and enforceability outcomes.

Manufacturing freedom-to-operate also requires review of:

formulation patents;
process patents;
crystallization or particle-size patents;
container and stability patents;
manufacturing know-how;
trademark rights in Epiduo and related brands; and
FDA-approved labeling requirements.

Key Takeaways

U.S. Patent 8,809,305 is a method-of-treatment patent associated with long-term use of adapalene and benzoyl peroxide.
Claim 1 requires a fixed-dose combination containing 0.1% to 0.3% adapalene and exactly 2.5% benzoyl peroxide.
The actives must be the only anti-acne active ingredients.
Treatment must occur at least once every two days for at least six months.
Claim 10 specifically covers the commercially important 0.1% adapalene/2.5% benzoyl peroxide formulation.
Claims 4, 5, 8 and 9 target daily or every-other-day treatment over nine- to twelve-month periods.
Claim 7 adds a gel limitation; claim 11 narrows the patient population by lesion count and excludes active nodules or cysts.
The patent has an expected ordinary term endpoint in September 2027, subject to official term adjustment.
The principal generic strategies are Paragraph IV litigation, a section viii carve-out, settlement-based entry or post-expiration launch.
The patent does not replace a full review of related Galderma formulation, process and regulatory patents.

FAQs

Does Patent 8,809,305 claim Epiduo itself?

No. It claims a method of treating acne using a fixed-dose adapalene and benzoyl peroxide combination. It does not broadly claim the adapalene molecule, benzoyl peroxide, or every formulation of Epiduo.

Can a product with 0.3% adapalene infringe Patent 8,809,305?

Yes, if it also contains 2.5% benzoyl peroxide as the only other anti-acne active and is used according to the claimed long-term regimen. Claim 1 expressly covers adapalene concentrations from 0.1% to 0.3% by weight.

Does a cream avoid the patent because claim 7 requires a gel?

Not necessarily. Claim 1 does not require a gel. A non-gel formulation may still fall within claim 1 if the remaining limitations are met. Claim 7 is limited to gels.

Does adding a third anti-acne ingredient avoid claim 1?

It may avoid claim 1 because the claim requires adapalene and benzoyl peroxide to be the only anti-acne active ingredients. Other claims and other patents could still create infringement risk.

Is a generic adapalene/benzoyl peroxide product automatically blocked until 2027?

No. The answer depends on current Orange Book listings, the generic label, Paragraph IV certifications, related patents, litigation outcomes and any settlement or license. A generic may pursue a carve-out, challenge the patent or enter after applicable patent barriers expire.

References

Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs, NDA 022320, Epiduo. U.S. Department of Health and Human Services.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,809,305, Method for treating acne with adapalene and benzoyl peroxide. Alexandria, VA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	065085	⤷ Start Trial
Australia	2008209730	⤷ Start Trial
Canada	2677167	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,809,305

Summary for Patent: 8,809,305